Vantive unveils latest in scientific support and innovation to advance lifesaving critical therapies for patients in intensive care

Vantive, a vital organ therapy company with a 70-year legacy of kidney care innovation, showcased new clinical evidence in support of Extracorporeal Blood Purification at the 6th Asia Pacific Acute Kidney Injury & Continuous Renal Replacement Therapy Conference 2025 in Bangkok (APAC AKI CRRT Conference 2025).

 

Vantive as sponsor for a consensus paper for Extracorporeal Blood Purification and a separate study of patients in the intensive care setting, joined with the clinical community at APAC AKI CRRT Conference 2025, announced the clinical support and showcased the company’s innovation in CRRT and multi-organ support. Developed by a group of Asia-Pacific experts, the two papers offer a perspective of sepsis and hyperinflammatory conditions; challenges that are also pressing concerns for Malaysian ICUs equip clinicians with capabilities needed to act decisively in the critical care setting.

Prof. Nattachai Srisawat, MD, PhD

Professor Nattachai Srisawat, MD, PhD from Thailand, lead author of the consensus said: “Our work to develop the consensus and promote its recommendations among clinicians across Asia Pacific at the AKI CRRT conference is a testament to the power of collaboration. By partnering with Vantive, we are able to take the latest research in acute kidney injury and translate it into practical, life-saving therapies that directly benefit patients in Thailand, Malaysia, and beyond. This is about building a regional network of expertise to combat organ failure more effectively.”

 

Prof. Pham Chi Ngoc Thao of Cho Ray Hospital, Vietnam

Professor Pham Chi Ngoc Thao of Cho Ray Hospital, Vietnam, who was involved in the consensus commented: “In critical care, every minute counts. Vantive's commitment to advancing multi-organ support gives clinicians a new level of confidence in the most challenging situations. This collaboration is crucial for institutions like Cho Ray Hospital, as it empowers us to adopt cutting-edge technologies and share our experiences to improve outcomes for our most critically ill patients in Vietnam, Malaysia and more.”

 

Showcasing intensive care innovation at regional forum in Bangkok

As a vital organ therapy company, Vantive is delivering on its mission to extend lives and expand possibilities. Vantive highlighted the research alongside the company’s innovation to extend the impact in CRRT and multi-organ support at the 6th Asia Pacific AKI CRRT Conference, held in Bangkok from October 2–4, 2025. The company's participation in the AKI CRRT conference reinforces its commitment to advancing critical care knowledge in collaboration with hospitals, ongoing research, and investment in education; an effort that holds particular significance for Malaysia, where AKI continues to be a key challenge in intensive care units and contributes to longer hospital stays and higher treatment costs.

 

Dr. Kuljinder Singh, APAC Medical Director, Vantive said: “As a leader in vital organ therapies, we are proud to work with the clinical community to advance lifesaving critical care therapies with systems capable of delivering continuous renal replacement therapy as well as multi-organ support. We continue to pursue novel diagnostic and therapeutic options including a new approach to sepsis management.” 

Dr. Kuljinder Singh, APAC Medical Director, Vantive

About Vantive 

Vantive is a global leader in vital organ therapies with a 70-year heritage in kidney care. The company partners with clinicians worldwide to deliver solutions that extend lives and expand possibilities for critically ill patients. To learn more, visit www.vantive.com and follow them on LinkedIn, X, Facebook, Instagram and YouTube.